A systematic review of foot ulcer in patients with type 2 diabetes mellitus. II: Treatment

Diabetic Medicine

Volumn 16, Issue 11, 1999, Pages 889-909

  Mason, James ^a   O'Keeffe, C ^b   Hutchinson, A ^b   McIntosh, A ^b   Young, R ^c   Booth, A ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Diabetes mellitus; Diabetic foot; Systematic review; Treatment

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CADEXOMER IODINE; CALCIUM ALGINATE; CEFALEXIN; CILASTATIN; CLINDAMYCIN; COTRIMOXAZOLE; DIMETHYL SULFOXIDE; GENTAMICIN; GROWTH FACTOR; IMIPENEM; KETANSERIN; METRONIDAZOLE; OFLOXACIN; PHENYTOIN; POLYURETHAN FOAM; SULTAMICILLIN;

ANTIBIOTIC THERAPY; DRUG EFFICACY; FOOT ULCER; HUMAN; HYPERBARIC OXYGEN; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PROTECTIVE CLOTHING; REVIEW; SKIN TRANSPLANTATION; TOPICAL DRUG ADMINISTRATION; WOUND CARE;

DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; EVIDENCE-BASED MEDICINE; HUMANS; MORBIDITY; PATIENT EDUCATION; PREVALENCE;

EID: 0032731902     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00137.x     Document Type: Review

References (40)

1. Mason JM, O'Keeffe C, McIntosh A, Hutchinson A, Booth A, Young R. A systematic review of foot ulcer in patients with Type 2 diabetes. I: Prevention. Diabet Med 1999; 16: 801-812.
2. Apelqvist J, Agardh C-D. The association between clinical risk factors and outcome of diabetic foot ulcers. Diabetes Res Clin Prac 1992; 18: 43-45.
3. Edmonds ME, Blundell MP, Morris ME, Cotton LT, Watkins PI. Improved survival of the diabetic foot: the role of the specialised foot clinic. Q J Medicine 1986; 60: 763-771.
4. Wagner FW. Algorithms of diabetic foot care. In Levin ME, O'Neal FW eds. The Diabetic Foot. St Louis: CV Mosby, 1983: 290.
5. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 1995; 48: 9-18.
6. Chantelau E, Tanudjaja T, Altenhöfer F, Ersanli Z, Lacigova S, Metzger C. Antibiotic Treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabetic Med 1996; 13: 156-159.
7. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990; 150: 790-797.
8. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: a comparison of two parenteral-to-oral regimens. Clin Infectious Diseases 1997; 24: 643-648.
9. Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI et al. Use of ampicillin/sulbactam versus imipenem/cilastitin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-693.
10. Hughes CE, Johnson CC, Bamberger DM, Reinhardt JF, Peterson LR, Mulligan ME et al. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin Therapeutics 1987; 10: 36-49.
11. File TM, Tan JS. Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections). Am J Medicine 1983; 75: 100-105.
12. Tan JS, Wishnow RM, Talan DA, Duncanson DA, Norden CW. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrobial Agents Chemotherapy 1993; 37: 1580-86.
13. Bradsher RW, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Medicine 1984 October; 19: 63-67.
14. Di Mauro C, Ossino AM, Trefiletti M, Polosa P, Beghe F. Lyophilized collagen in the treatment of diabetic ulcers. Drugs Exptl Clin Res 1991; 17: 371-373.
15. Ahroni JH, Boyko FJ, Pecoraro RE. Diabetic foot ulcer healing: extrinsic vs intrinsic factors. Wounds 1993; 5: 245-255.
16. Blackman JD, Senseng D, Quinn L, Mazzone T. Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetes foot ulcers. Diabetes Care 1994; 17: 322-325.
17. Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Rep Reg 1994; 2: 59-69.
18. Apelqvist J, Tennvall GR. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. Acta Derm Venereol (Stockholm) 1996; 76: 231-235.
19. Donaghue VM, Chrzan JS, Rosenblum BI et al. A Clinical Evaluation of a Collagen-Alginate Topical Wound Dressing the Management of Diabetic Foot Ulcers. Diabetes 1996 Electronic Highlights Bulletin. 56th Annual Meeting of the American Diabetes Association.
20. Lishner M, Lang R, Kedar I, Ravid M. Treatment of diabetic perforating ulcers (mal perforant) with local dimethylsulfoxide. J Am Geriatr Soc 1985; 33: 41-43.
21. Muthukumarasamy MC, Sivakumar G, Manoharan G. Topical phenytoin in diabetic foot ulcers. Diabetes Care 1991; 4: 909-911.
22. British National Formulary Number 35. London: The British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1988.
23. Foster AVM, Greenhill MT, Edmonds ME. Comparing two dressings in the treatment of diabetic foot ulcers. J Wound Care 1994; 3: 224-228.
24. Clever HU, Dreyer M. Comparing two wound dressings for the treatment of neuropathic diabetic foot ulcers. In Proceedings of the 5th European Conference on Advances in Wound Management London: MacMillan, 1996: 201-203.
25. Gentzkow G, Iawaski S, Hershon K, Mengel M, Prendergast J, Ricotta J et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350-354.
26. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs 1997; 21: 1203-1210.
27. Mueller MJ, Diamond JE, Sinacore DR, Delitto A, Blair III V, Drury D et al. Total contact casting in treatment of diabetic planter ulcers. Controlled clinical trial. Diabetes Care 1989; 12: 384-388.
28. Leslie C, Sapico F, Ginunas V, Adkins R. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 1988; 11: 111-115.
29. Faglia E, Favales F, Aldeghi A, Patrizia C, Quarantiello A, Oriani G et al. Adjunctive systemic hyperbaric oxygen therapy in the treatment of severe prevalently ischemic diabetic foot ulcers. Diabetes Care 1996; 19: 1338-1343.
30. Apelqvist J, Castenfors J, Larsson J, Stenstrom A, Persson G. Ketanserin in the treatment of diabetic foot ulcers with severe PVD. Int Angiol 1990; 9: 120-124.
31. Martinez-de Jesus FR, Morales-Guzman M, Castañeda M, Perez-Morales A, Garcia-Alonso J, Mendiola-Segura I. Randomised single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers. Arch Med Research 1997; 28: 95-99.
32. Steed D, Goslen J, Holloway G, Malone J, Bunt T, Webster M. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. Diabetes Care 1992; 15: 1598-1604.
33. Holloway G, Steed D, DeMarco M, Masmuto T, Moosa H, Webster M et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, non-healing diabetic wounds. Wounds 1993; 5: 198-206.
34. Steed D, Ricotta J, Prendergast J, Kaplan R, Webster M, McGill J et al. and the RGD Study Group. Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid (RGD) peptide matrix. Diabetes Care 1995; 18: 1-8.
35. Richard J, Richard C, Daures J, Clouer S, Vannereau D, Bringer J et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. Diabetes Care. 1995; 18: 64-69.
36. Steed D, Donohoe D, Webster M, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996; 183: 61-64.
37. Wieman TJ, Smiell JM, Yachin S. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neurpoathic diabetic ulcers. Diabetes Care 1998; 21: 822-827.
38. Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 855-859.
39. Malone JM, Snyder M, Anderson G, Bernhard VM, Holloway GA, Bunt TJ. Prevention of Amputation by Diabetic Education. Am J Surgery 1989; 158: 520-524.
40. World Health Organisation (Europe) and International Diabetes Federation (Europe). Diabetes care and research in Europe: The St Vincent Declaration. Diabetic Med 1990; 7: 360.